Prazosin labels and packages: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Prazosin}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFI...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
PRINCIPAL DISPLAY PANEL - 1 mg Capsule Bottle Label | |||
Pfizer | |||
NDC 0069-4310-71 | |||
Minipress® | |||
(prazosin hydrochloride) | |||
1 mg* | |||
Capsules | |||
250 Capsules | |||
Rx only | |||
{| | |||
| [[image:prazosin3.jpg|400px|thumb]] | |||
|} | |||
PRINCIPAL DISPLAY PANEL - 2 mg Capsule Bottle Label | |||
Pfizer | |||
NDC 0069-4370-71 | |||
Minipress® | |||
(prazosin hydrochloride) | |||
2 mg* | |||
Capsules | |||
250 Capsules | |||
Rx only | |||
{| | |||
| [[image:prazosin4.jpg|400px|thumb]] | |||
|} | |||
PRINCIPAL DISPLAY PANEL - 5 mg Capsule Bottle Label | |||
Pfizer | |||
NDC 0069-4380-71 | |||
Minipress® | |||
(prazosin hydrochloride) | |||
5 mg* | |||
Capsules | |||
250 Capsules | |||
Rx only | |||
{| | |||
[[image:prazosin5.jpg|400px|thumb]] | |||
|} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc | publisher = | date = | accessdate = 6 March 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc | publisher = | date = | accessdate = 6 March 2014 }}</ref> | ||
Revision as of 00:53, 7 March 2014
| Prazosin |
|---|
| Prazosin®, Minipress® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Prazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
PRINCIPAL DISPLAY PANEL - 1 mg Capsule Bottle Label
Pfizer NDC 0069-4310-71
Minipress® (prazosin hydrochloride)
1 mg* Capsules
250 Capsules Rx only
 |
PRINCIPAL DISPLAY PANEL - 2 mg Capsule Bottle Label
Pfizer NDC 0069-4370-71
Minipress® (prazosin hydrochloride)
2 mg* Capsules
250 Capsules Rx only
 |
PRINCIPAL DISPLAY PANEL - 5 mg Capsule Bottle Label
Pfizer NDC 0069-4380-71
Minipress® (prazosin hydrochloride)
5 mg* Capsules
250 Capsules Rx only
References
- ↑ "MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC]". Retrieved 6 March 2014.